An evaluation of ferric derisomaltose as a treatment for anemia

References

• Bhandari S, Pereira DIA, Chappell HF, et al. Intravenous irons: from basic science to clinical practice. Pharmaceuticals. 2018;11(3):82. MDPI.
   Web of Science ®Google Scholar
• Vos T, Abajobir AA, Abbafati C, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: A systematic analysis for the global burden of disease study 2016. Lancet. 2017;390:1211–1259. Elsevier
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Comin-Colet J, de Francisco A, et al. Iron deficiency across chronic inflammatory conditions: international expert opinion on definition, diagnosis, and management. Am J Hematol. 2017;92:1068–1078.
   PubMed Web of Science ®Google Scholar
• Aksan A, Işık H, Radeke HH, et al. Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017;10:p. 1303–18. 10.1111/apt.14043
   Web of Science ®Google Scholar
• Kalra PA, Bhandari S. Efficacy and safety of iron isomaltoside (Monofer®) in the management of patients with iron deficiency anemia. Int J Nephrol Renovasc Dis Dove Press. 2016;9:53–64.
   PubMed Web of Science ®Google Scholar
• Avni T, Bieber A, Grossman A, et al., The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc. 90(1): 12–23. 2015; .
   PubMed Web of Science ®Google Scholar
• Musallam KM, Tamim HM, Richards T, et al. Preoperative anaemia and postoperative outcomes in non-cardiac surgery: A retrospective cohort study. Lancet. 2011;378:1396–1407.
   PubMed Web of Science ®Google Scholar
• Muñoz M, Gómez-Ramírez S, Campos A, et al. Pre-operative anaemia: prevalence, consequences and approaches to management. Blood Transfus. 2015;13(3):370–379.
   Web of Science ®Google Scholar
• Grosso MJ, Boddapati V, Cooper HJ, et al. The effect of preoperative anemia on complications after total hip arthroplasty. J Arthroplasty. 2020;35:S214–8.
   PubMedGoogle Scholar
• Aly SS, Fayed HM, Ismail AM, et al. Assessment of peripheral blood lymphocyte subsets in children with iron deficiency anemia. BMC Pediatr. 2018;18(1):49.
   PubMedGoogle Scholar
• Jiang Y, Li C, Wu Q, et al. Iron-dependent histone 3 lysine 9 demethylation controls B cell proliferation and humoral immune responses. Nat Commun. 2019;10(1):2935.
   Web of Science ®Google Scholar
• NICE Guideline NG8. Chronic kidney disease: managing anemia. [Internet]. 2015 [ cited 2020 Jul 7]. Available from: https://www.nice.org.uk/guidance/ng8
   Google Scholar
• Mikhail A, Brown C, Williams JA, et al. Renal association clinical practice guideline on anaemia of chronic kidney disease. BMC Nephrol BioMed Central. 2017;18(1):345. .
   PubMedGoogle Scholar
• KIDGO Work Group, Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease [Internet]. Kidney Int Suppl. 2012; Available from: http://kdigo.org/home/guidelines/anemia-in-ckd/%5Cnhttp://linkinghub.elsevier.com/retrieve/pii/S2157171615310777
   Web of Science ®Google Scholar
• Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohn’s Colitis. 2015;9(3):211–222. .
   Google Scholar
• Anaemia - iron deficiency | topics A to Z | CKS | NICE [Internet]. [cited 2020 Oct 13]. Available from: https://cks.nice.org.uk/topics/anaemia-iron-deficiency/
   Google Scholar
• Boone S, Powers JM, Goodgame B, et al. Identification and management of iron deficiency anemia in the emergency department. J Emerg Med. 2019;57(5):637–645.
   PubMed Web of Science ®Google Scholar
• Motta I, Mantovan G, Consonni D, et al. Treatment with ferric carboxymaltose in stable patients with severe iron deficiency anemia in the emergency department. Intern Emerg Med. 2020;15(4):629–634. .
   PubMed Web of Science ®Google Scholar
• Tolkien Z, Stecher L, Mander AP, et al. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: A systematic review and meta-analysis. PLoS One Public Lib Sci. 2015;10(2):e0117383–e0117383. .
   PubMed Web of Science ®Google Scholar
• Kalra PA, Bhandari S. Safety of intravenous iron use in chronic kidney disease. Curr Opin Nephrol Hypertens. 2016;25:529–535. . Wolters Kluwer Health
   PubMed Web of Science ®Google Scholar
• Di Francesco T, Philipp E, Borchard G. Iron sucrose: assessing the similarity between the originator drug and its intended copies. Ann N Y Acad Sci. 2017;1407(1):63–74. . John Wiley & Sons, Ltd
   PubMed Web of Science ®Google Scholar
• Jahn MR, Andreasen HB, Fütterer S, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer®), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm. 2011;78:480–491.
   PubMed Web of Science ®Google Scholar
• Gustafson HH, Holt-Casper D, Grainger DW, et al. Nanoparticle uptake: the phagocyte problem.Nano Today. 2015;10(4):487–510. .
   PubMed Web of Science ®Google Scholar
• Garbowski MW, Bansal SS, Porter JB, et al. NTBI Is transiently generated from two compartments during a single dose of intravenous iron - a randomized controlled clinical study. Blood. 2019;134:2234–2235.
   Web of Science ®Google Scholar
• Zager RA, Johnson ACM, Hanson SY. Parenteral iron nephrotoxicity: potential mechanisms and consequences. Kidney Int. 2004;66:144–156. . Elsevier
   PubMed Web of Science ®Google Scholar
• Fell LH, Zawada AM, Rogacev KS, et al. Distinct immunologic effects of different intravenous iron preparations on monocytes. Nephrol Dial Transplant. 2014;29(4):809–822. . Oxford University Press
   PubMed Web of Science ®Google Scholar
• Litton E, Xiao J, Ho KM. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. BMJ. 2013;347:f4822.
   PubMed Web of Science ®Google Scholar
• Nordfjeld K, Andreasen H, Thomsen LL. Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease. Drug Des Devel Ther Dove Press. 2012;6:43–51.
   PubMed Web of Science ®Google Scholar
• Gupta DR, Larson DS, Thomsen LL, et al. Pharmacokinetics of iron isomaltoside1000 in patients with stage 5 chronic kidney disease on dialysis therapy. J Drug Metab Toxicol. 2013;04.
   Google Scholar
• Pharmacosmos UK Limited. SmPC: monofer 100mg/ml solution for injection/infusion [Internet]. EMC; 2020 [ cited 2020 Oct 13]. Available from: https://www.medicines.org.uk/EMC/medicine/23669/SPC/Monofer+100mg+ml+solution+for+injection+infusion/#gref
   Google Scholar
• Derman R, Roman E, Modiano MR, et al., A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia. Am J Hematol. 92(3): 286–291. 2017; .
   PubMed Web of Science ®Google Scholar
• Auerbach M, Henry D, Derman RJ, et al. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial. Am J Hematol. 2019;94(9):1007–1014. Wiley Online Library. .
   PubMed Web of Science ®Google Scholar
• Wolf M, Rubin J, Achebe M, et al. Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials. JAMA - J Am Med Assoc. 2020;323:432–443.
   PubMed Web of Science ®Google Scholar
• Gybel-Brask M, Seeberg J, Thomsen LL, et al. Intravenous iron isomaltoside improves hemoglobin concentration and iron stores in female iron-deficient blood donors: a randomized double-blind placebo-controlled clinical trial. Transfusion. 2018;58(4):974–981.
   PubMed Web of Science ®Google Scholar
• Kalra PA, Bhandari S, Saxena S, et al., A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrol Dial Transplant. 31(4): 646–655. 2016; .
   PubMed Web of Science ®Google Scholar
• Bhandari S, Kalra PA, Kothari J, et al. A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients. Nephrol Dial Transplant. 2015;30:1577–1589.
   PubMed Web of Science ®Google Scholar
• Bhandari S, Kalra PA, Berkowitz M et al. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial.. Nephrol Dial Transplant. 2020; [Online ahead of print]. 10.1093/ndt/gfaa011.
   PubMed Web of Science ®Google Scholar
• Wikström B, Bhandari S, Barany P, et al. Iron isomaltoside 1000: A new intravenous iron for treating iron deficiency in chronic kidney disease. J Nephrol. 2011;24(5):589–596. .
   PubMed Web of Science ®Google Scholar
• Jensen G, Gøransson LG, Fernström A, et al. Treatment of iron deficiency in patients with chronic kidney disease: A prospective observational study of iron isomaltoside (NIMO Scandinavia). Clin Nephrol. 2019;91(4):246–253. .
   PubMed Web of Science ®Google Scholar
• Jesus-Silva JA, Lamplugh A, Dhada S, et al. Conversion of haemodialysis patients from iron sucrose to iron isomaltoside: a real-world experience. BMC Nephrol. 2020;21(1):212. .
   PubMed Web of Science ®Google Scholar
• Mikhail AI, Schön S, Simon S, et al. A prospective observational study of iron isomaltoside in haemodialysis patients with chronic kidney disease treated for iron deficiency (DINO). BMC Nephrol. 2019.
   PubMed Web of Science ®Google Scholar
• Biggar P, Leistikow F, Walper A. A prospective observational study of effectiveness and safety of iron isomaltoside in patients with chronic renal failure and iron deficiency anemia. Clin Nephrol. 2016;86(12):310–318.
   PubMedGoogle Scholar
• Semrin G, Fishman DS, Bousvaros A, et al. Impaired intestinal iron absorption in Crohn’s disease correlates with disease activity and markers of inflammation. Inflamm Bowel Dis. 2006;12(12):1101–1106. .
   PubMed Web of Science ®Google Scholar
• Bregman DB, Morris D, Koch TA, et al. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia. Am J Hematol. 2013;88:97–101.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Staun M, Tandon RK, et al., A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (monofer) compared with oral iron for treatment of anemia in ibd (proceed). Am J Gastroenterol. 108(12): 1877–1888. 2013; .
   PubMed Web of Science ®Google Scholar
• Reinisch W, Altorjay I, Zsigmond F, et al. A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease. Scand J Gastroenterol. 2015;50(10):1226–1233. .
   PubMed Web of Science ®Google Scholar
• Dahlerup JF, Jacobsen BA, van der Woude J, et al., High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23. Scand J Gastroenterol. 51(11): 1332–1338. 2016; .
   PubMed Web of Science ®Google Scholar
• Frigstad SO, Haaber A, Bajor A, et al. The NIMO scandinavian study: a prospective observational study of iron isomaltoside treatment in patients with iron deficiency. Gastroenterol Res Pract. 2017.
   PubMed Web of Science ®Google Scholar
• Stein J, Walper A, Klemm W, et al. A. Safety and efficacy of intravenous iron isomaltoside for correction of anaemia in patients with inflammatory bowel disease in everyday clinical practice. Scand J Gastroenterol. 2018;53(9):1059–1065. .
   PubMed Web of Science ®Google Scholar
• Kearns J, Jacob SG. Real-world evaluation of an intravenous iron service for the treatment of iron deficiency in patients with gastroenterological disorders. Frontline Gastroenterol. 2020. DOI:10.1136/flgastro-2020-101406
   PubMedGoogle Scholar
• Holm C, Thomsen LL, Norgaard A, et al. Single-dose intravenous iron infusion or oral iron for treatment of fatigue after postpartum haemorrhage: a randomized controlled trial. Vox Sang. 2017;112:219–228. .
   PubMed Web of Science ®Google Scholar
• Holm C, Thomsen LL, Langhoff-Roos J. Intravenous iron isomaltoside treatment of women suffering from severe fatigue after postpartum hemorrhage. J Matern Neonatal Med. 2019;32(17):2797–2804.
   PubMed Web of Science ®Google Scholar
• Holm C, Thomsen LL, Norgaard A, et al. Single-dose intravenous iron infusion versus red blood cell transfusion for the treatment of severe postpartum anaemia: a randomized controlled pilot study. Vox Sang. 2017;112(2):122–131.
   PubMed Web of Science ®Google Scholar
• Wesström J. Safety of intravenous iron isomaltoside for iron deficiency and iron deficiency anemia in pregnancy. Arch Gynecol Obstet. 2020;301(5):1127–1131. Available from:. [Internet]Springer Berlin Heidelberg.
   PubMed Web of Science ®Google Scholar
• Derman R, Roman E, Smith-Nguyen GN, et al. Iron isomaltoside is superior to iron sucrose in increasing hemoglobin in gynecological patients with iron deficiency anemia. Am J Hematol. 2018;93(6):E148–E150.
   PubMed Web of Science ®Google Scholar
• Birgegård G, Henry D, Glaspy J, et al. A randomized noninferiority trial of intravenous iron isomaltoside versus oral iron sulfate in patients with nonmyeloid malignancies and anemia receiving chemotherapy: the profoun trial. Pharmacotherapy. 2016; (4): p. 402–14. DOI: 10.1002/phar.1729.
   PubMed Web of Science ®Google Scholar
• Ng O, Keeler B, Simpson JA, et al. Feasibility of Intravenous Iron Isomaltoside to Improve Anemia and Quality of Life During Palliative Chemotherapy for Esophagogastric Adenocarcinoma. Nutr Cancer. 2018;70:1106–1117.
   PubMed Web of Science ®Google Scholar
• Anker SD, Colet JC, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436–2448.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36:657–668.
   PubMed Web of Science ®Google Scholar
• Van Veldhuisen DJ, Ponikowski P, Van Der Meer P, et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation. 2017; (15):p. 1374–83. DOI: 10.1161/CIRCULATIONAHA.117.027497.
   Web of Science ®Google Scholar
• Hildebrandt PR, Bruun NE, Nielsen OW, et al. Effects of administration of iron isomaltoside 1000 in patients with chronic heart failure. A Pilot Study. 2010;11:131–137. Transfus Altern Transfus Med
   Google Scholar
• Charles-Edwards G, Amaral N, Sleigh A, et al., Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency: ferric-hf ii randomized mechanistic trial. Circulation. 139(21): 2386–2398. 2019; .
   PubMed Web of Science ®Google Scholar
• Bhandari S, Allgar V, Lamplugh A, et al. Protocol and baseline data of a multicentre prospective double-blinded randomized study of intravenous iron on functional status in patients with chronic kidney disease. Am J Nephrol. 2020;51(6):493–500. .
   PubMed Web of Science ®Google Scholar
• Muñoz M, Acheson AG, Auerbach M, et al. International consensus statement on the peri-operative management of anaemia and iron deficiency. Anaesthesia. 2017;72(2):233–247.
   PubMed Web of Science ®Google Scholar
• Johansson PI, Rasmussen AS, Thomsen LL. Intravenous iron isomaltoside 1000 (Monofer) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical trial (thePROTEC trial). Vox Sang. 2015;109(3):257–266.
   PubMed Web of Science ®Google Scholar
• Won Suh D, Han SB, Park JH, et al. Intravenous iron supplementation with intra-articular administration of tranexamic acid reduces the rate of allogeneic transfusions after simultaneous bilateral total knee arthroplasty. Blood Transfus. 2017;15:506–511.
   PubMed Web of Science ®Google Scholar
• Fishbane S, Ungureanu VD, Maesaka JK, et al. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis. 1996;28(4):529–534. .
   PubMed Web of Science ®Google Scholar
• Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. Lancet. 2007;9572:p. 1502–4. DOI:10.1016/S0140-6736(07)60689-8
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Vernon K. Complement activation-relatedpseudo-allergy: a fresh look at hypersensitivity reactions to intravenous iron. Am J Nephrol. 2017;45(1):60–62.
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Bock AH, Carrera F, et al. FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant. 2014;29(11):2075–2084. .
   PubMed Web of Science ®Google Scholar
• Ishida JH, Marafino BJ, McCulloch CE, et al. Receipt of intravenous iron and clinical outcomes among hemodialysis patients hospitalized for infection. Clin J Am Soc Nephrol. 2015;10(10):1799–1805. .
   PubMed Web of Science ®Google Scholar
• Agarwal R, Kusek JW, Pappas MK. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int. 2015;88:905–914
   PubMed Web of Science ®Google Scholar
• Macdougall IC, White C, Anker SD, et al. Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med. 2019;380:447–458.
   PubMed Web of Science ®Google Scholar
• Ziedan A, Bhandari S. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IR. Trials. 2019;20(1):194.
   PubMedGoogle Scholar
• Kassianides X, Zeidan A, Bhandari S. So051Prospective open-label explorative randomised single centre comparative study to determine the effects of various intravenous iron preparations on haemoglobin, haemetenics, markers of kidney function, quality of Life and Safety. Nephrol Dial Transplant. 2020;35(Supple_3).
   Web of Science ®Google Scholar
• Kassianides X, Zeidan A, Sturmey R, et al. P0848Prospective open-label explorative randomised single-centre comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (iron-ckd). Nephrol Dial Transplant. 2020;35(Supple_3).
   Web of Science ®Google Scholar
• Sivakumar C, Jubb VM, Lamplugh A, et al. Safety of intravenous Iron - Cosmofer and monofer therapy in peritoneal dialysis and Non-Dialysis-Dependent chronic kidney disease patients. Perit Dial Int. 2019;39(2):192–195.
   PubMed Web of Science ®Google Scholar
• Pollock RF, Biggar P. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia. Expert Rev Hematol. 2020;13(2):187–195. .
   PubMed Web of Science ®Google Scholar
• Achebe M, DeLoughery TG. Clinical data for intravenous iron – debunking the hype around hypersensitivity. Transfusion. 2020;60(6):1154–1159. .
   PubMed Web of Science ®Google Scholar
• Qassim A, Mol BW, Grivell RM, et al. Safety and efficacy of intravenous iron polymaltose, iron sucrose and ferric carboxymaltose in pregnancy: A systematic review. Aust New Zeal J Obstet Gynaecol. 2018;1:p. 22–39. DOI: 10.1111/ajo.12695
   Web of Science ®Google Scholar
• Holm C, Thomsen LL, Norgaard A, et al. Iron concentration in breast milk normalised within one week of a single high-dose infusion of iron isomaltoside in randomised controlled trial. Acta Paediatr Int J Paediatr. 2017;106(2):256–260. .
   PubMed Web of Science ®Google Scholar
• Glaspy JA, Lim-Watson MZ, Libre MA, et al. Hypophosphatemia associated with intravenous iron therapies for iron deficiency anemia: A systematic literature review. <![cdata[therapeutics and Clinical Risk Management]]>. 2020;16:245–259.
   PubMed Web of Science ®Google Scholar
• Holm C, Thomsen LL, Norgaard A, et al. Iron content in breast milk from mothers treated with a high single dose infusion of iron isomaltoside 1000 (Monofer). Int J Gynecol Obs. 2015;131:E119.
   Google Scholar
• Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013;28(8):1793–1803. Wiley Online Library. .
   PubMed Web of Science ®Google Scholar
• Detlie TE, Lindstrøm JC, Jahnsen ME, et al. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside. Aliment Pharmacol Ther. 2019;50(4):397–406. .
   PubMed Web of Science ®Google Scholar
• Bager P, Hvas CL, Dahlerup JF. Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions. Br J Clin Pharmacol. 2017;83(5):1118–1125.
   PubMed Web of Science ®Google Scholar
• Schaefer B, Würtinger P, Finkenstedt A, et al. Choice of high-dose intravenous iron preparation determines hypophosphatemia risk. PLoS One. 2016;11(12):e0167146. .
   PubMed Web of Science ®Google Scholar
• Bhandari S. A hospital-based cost minimization study of the potential financial impact on the UK health care system of introduction of iron isomaltoside 1000. Ther Clin Risk Manag. 2011;103–113. 10.2147/TCRM.S17536
   PubMed Web of Science ®Google Scholar
• Bhandari S. Update of a comparative analysis of cost minimization following the introduction of newly available intravenous iron therapies in hospital practice. Ther Clin Risk Manag. 2011;501–509.DOI: 10.2147/TCRM.S25882
   PubMed Web of Science ®Google Scholar
• Pollock RF, Muduma G. A budget impact analysis of parenteral iron treatments for iron deficiency anemia in the UK: reduced resource utilization with iron isomaltoside 1000. Clin Outcomes Res. 2017;9:475–483.
   PubMed Web of Science ®Google Scholar
• Pollock RF, Muduma G. Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK. Expert Opin Drug Deliv. 2017;14(12):1439–1446.
   PubMed Web of Science ®Google Scholar
• Pollock RF, Muduma G. an economic evaluation of iron isomaltoside 1000 versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in denmark. Adv Ther. 2018;35(12):2128–2137.
   PubMed Web of Science ®Google Scholar
• Pollock RF, Muduma G. A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom. J Med Econ. 2020;23(7):751–759.
   Web of Science ®Google Scholar
• Loughnane F, Muduma G, Pollock RF. Development of a resource impact model for clinics treating pre-operative iron deficiency anemia in ireland. Adv Ther. 2020;37:1218–1232.
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Bhandari S, White C, et al. Intravenous iron dosing and infection risk in patients on hemodialysis: a prespecified secondary analysis of the pivotal trial. J Am Soc Nephrol. 2020;31(5):1118–1127. .
   PubMed Web of Science ®Google Scholar
• Strauss WE, Dahl NV, Vadhan-Raj S, et al. Effects of IV iron treatment with ferumoxytol on health-related quality of life of patients with iron deficiency anemia. J Community Support Oncol. 2016;14:342–350.
   Google Scholar
• Keeler BD, Dickson EA, Simpson JA, et al. The impact of pre-operative intravenous iron on quality of life after colorectal cancer surgery: outcomes from the intravenous iron in colorectal cancer-associated anaemia (IVICA) trial. Anaesthesia. 2019;74(6):714–725.
   PubMed Web of Science ®Google Scholar
• García-López S, Bocos JM, Gisbert JP, et al. High-dose intravenous treatment in iron deficiency anaemia in inflammatory bowel disease: early efficacy and impact on quality of life. Blood Transfus. 2016;14:199–205.
   PubMed Web of Science ®Google Scholar
• Pergola PE, Fishbane S, Ganz T. Novel oral iron therapies for iron deficiency anemia in chronic kidney disease. Adv Chronic Kidney Dis. 2019;4:p. 272–91. DOI:10.1053/j.ackd.2019.05.002
   PubMed Web of Science ®Google Scholar
• Gasche C, Ahmad T, Tulassay Z, et al. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program. Inflamm Bowel Dis. 2015;21(3):579–588.
   PubMed Web of Science ®Google Scholar
• Gupta N, Wish JB. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD. Am J Kidney Dis. 2017;6:p. 815–26. DOI: 10.1053/j.ajkd.2016.12.011
   Web of Science ®Google Scholar